Why the study?
Data deploying PFA for VT ablation in humans are scarce, and its use for VT ablation in congenital heart disease had not been reported.
Does pulsed field ablation prevent recurrent ventricular tachycardia in a patient with Ebstein's anomaly?
Does pulsed field ablation prevent recurrent ventricular tachycardia in a patient with Ebstein's anomaly?
Pulsed field ablation may be a safe and effective treatment for recurrent ventricular tachycardia in patients with congenital heart disease such as Ebstein's anomaly, particularly when prior radiofrequency ablation has failed.
Answers are grounded in this paper and cite their sources.
PFA appears feasible for VT in Ebstein’s anomaly; hypothesis-generating and requires prospective validation before broader adoption.
We report on a 33-year-old patient with Ebstein’s anomaly (EA) of the tricuspid valve who had recurrent episodes of sustained monomorphic ventricular tachycardia (VT). After the first episodes of VT 8 years ago, he had radiofrequency ablation (RFA) of VT within the atrialized right ventricle (aRV) and implantation of an extracardiac implantable cardioverter defibrillator (ICD) system. Implantation of endocardial ICD systems from the superior vena cava was technically not feasible after creation of a bidirectional Glenn shunt at an age of 15 years. The patient now presented with recurrent episodes of monomorphic VT and adequate ICD discharges. He was started on amiodarone and catheter ablation of VT was planned. As the patient had RFA of VT in the past, off-label application of pulsed field ablation (PFA) for ablation of the VT substrate was discussed with the patient. After obtaining written informed consent, electrophysiological study (EPS) was performed under general anaesthesia. Clinical VT with a cycle length of 285 ms could reproducibly be induced by programmed ventricular stimulation (Figure 1A). The current VT morphology and cycle length were identical to the VT targeted 8 years before. At that time, VT had been non-inducible after RF ablation of an anatomical isthmus within the aRV. For identification of VT substrate, a high-density voltage map as well as an isochronal late activation (ILA) map was obtained. Voltage mapping and the ILA map delineated the VT substrate at the anterior part of the aRV, exhibiting a zone of local abnormal ventricular activities (LAVA) located at the junction between the aRV and right ventricle (RV) (Figure 1B, C). (A) Twelve-lead ECG of the patient’s VT exhibiting superior QRS axis with a cycle length of 285 ms (25 mm/s). (B, C) Substrate map of the RV (anterior–posterior view). B shows a voltage map of the RV with a low voltage at the anterior aspect of the RV. This area corresponds to the actual location of the tricuspid valve (asterisk). The isochronal late activation map (C) exhibits local abnormal ventricular activities at the same site (circle). Arrows: suggested reentry circuit. (D) Fluoroscopic image of the Farawave™ ablation catheter (asterisk) at the site of late abnormal ventricular activation (RAO 30° view). (E) Voltage map of the RV after pulsed field ablation. No residual ventricular electrograms were recordable from the ablation site within the aRV (aPSE: atrial pace–sense electrode; aRV: atrialized right ventricle; RV: right ventricle; RVOT: right ventricular outflow tract; SC: shock coil; vPSE: ventricular pace–sense electrode). For pulsed field ablation, the Farawave™ ablation catheter (Farapulse, Boston Scientific, Marlborough, USA) was placed in its flower configuration at the site of LAVA/low voltage (Figure 1D). After a total of 35 applications, VT was no longer inducible and re-mapping of aRV voltage failed to show residual ventricular electrograms at the ablation site (Figure 1E). After pulsed field ablation of VT, the patient was closely followed for a total of 3 months so far at the outpatient clinic of our institution. No further episodes of VT were documented, neither on electrocardiogram (ECG) and Holter monitoring nor on ICD telemetry, and no further ICD discharges occurred since then. Pulsed field ablation is a new, non-thermal energy source approved for catheter ablation of paroxysmal AF with promising midterm effects.1 Data deploying PFA for ablation of VT in humans are scarce and limited to a single case report.2 To date, its use for VT ablation in patients with congenital heart disease (CHD) has not been reported yet. Patients with EA are known to be at increased risk for sustained VT and sudden cardiac death.3 Ventricular tachycardia substrate is most commonly found within the aRV. Based on current experience, catheter ablation of VT in EA has been judged to be reasonable treatment.4 Catheter ablation of VT in adult patients with CHD showed promising results,5 but VT recurrence is not rare. In the patient presented, VT recurred after RFA of tachycardia substrate within the aRV. One reason for recurrence may be incomplete ablation of the tachycardia substrate. Accordingly, catheter ablation using PFA was considered as PFA has been shown to induce deeper lesions compared with RFA in ventricular myocardium in a swine model.6 In addition, selective destruction of cardiomyocytes adds a special safety profile. Compared with ablation of AF, a higher number of PFA applications were required to reach the procedural endpoint (i.e. non-inducibility of clinical VT and complete elimination of the entire VT substrate) in the present case. After a lower number of PFA applications, the patient’s VT was still inducible and ventricular electrograms were recordable from the ablation site. As right ventricular myocardium is much thicker compared with left atrial myocardium (especially in subjects with RV volume overload as found in EA), the larger myocardial mass might have been the main reason necessitating larger number of PFA applications in the ventricle compared with pulmonary vein ostia (when using PFA for ablation of atrial fibrillation). The present case demonstrates that PFA can be safely and highly effectively used for ablation of VT in patients with CHD. Especially, those patients with recurrent VT after RFA and/or hypertrophied myocardium might be good candidates for PFA of VT. Ethical approval: The study was approved by the institutional review board. Consent: Written informed consent for scientific use of the data was obtained from the patient. Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The data underlying this article will be shared on reasonable request to the corresponding author.
No takes yet. Share an insight, caveat, or question.
Krause et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: